ResMed Inc (FRA:RMEA)
€ 19.7 0.1 (0.51%) Market Cap: 29.72 Bil Enterprise Value: 30.58 Bil PE Ratio: 33.47 PB Ratio: 6.91 GF Score: 97/100

Resmed Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 05:00PM GMT
Release Date Price: €10.4 (+2.97%)
Chris Cooper
Goldman Sachs Group Inc., Research Division - Research Analyst

Okay. I think in the interest time, let's make a start. So welcome again to day 1 of the Goldman Sachs Global Healthcare Conference. My name is Chris Cooper, I'm the Australian healthcare analyst. So today we've got Rob Douglas, the COO of ResMed. Thanks very much for joining us. I think Rob would just like to make a brief sort of introductory remark just to kind of set the scene.

Robert A. Douglas
ResMed Inc. - President & COO

Yes. Thanks, Chris. Thank you for having us here. I think you all know ResMed, we don't need to talk about sleep apnea and the fact that there is over 900 million untreated sleep apnea patients around the world and the fact that most of them don't know that they need their treatment. And so we've got a great opportunity still growing that core business and lots of our strategic moves are in -- around supporting that. Recently we've invested in also our COPD business. With our ventilators and our oxygen, we treat only a small proportion of COPD patients, but

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot